These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29278535)

  • 41. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Precision medicine in AML: overcoming resistance.
    Urrutia S; Takahashi K
    Int J Hematol; 2024 Oct; 120(4):439-454. PubMed ID: 39085680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT; Blonquist TM; Hernandez D; Amrein PC; Ballen KK; McMasters M; Avigan DE; Joyce R; Logan EK; Hobbs G; Brunner AM; Joseph C; Perry AM; Burke M; Behnan T; Foster J; Bergeron MK; Moran JA; Ramos AY; Som TT; Rae J; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Levis MJ
    Cancer; 2018 Jan; 124(2):306-314. PubMed ID: 28960265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Novel therapies in AML and their resistance mechanisms].
    Takahashi K
    Rinsho Ketsueki; 2022; 63(9):1052-1057. PubMed ID: 36198529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

  • 49. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
    Loschi M; Sammut R; Chiche E; Cluzeau T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
    Langdon WY
    Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
    Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
    Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
    Hogan FL; Williams V; Knapper S
    Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.
    Gołos A; Góra-Tybor J; Robak T
    Expert Opin Investig Drugs; 2023 Jan; 32(1):53-67. PubMed ID: 36669827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
    Ghiaur G; Levis M
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
    Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
    Marconi G; Giannini MB; Bagnato G; Simonetti G; Cerchione C; Mosquera Orgueira A; Musuraca G; Martinelli G
    Expert Opin Drug Saf; 2021 Jul; 20(7):791-799. PubMed ID: 33853481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.